Search

Your search keyword '"Matsubara N"' showing total 953 results
Start Over Author "Matsubara N"
953 results on '"Matsubara N"'

102. RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Author

Petrylak, D.P., primary, Sternberg, C.N., additional, Drakaki, A., additional, de Wit, R., additional, Nishiyama, H., additional, Necchi, A., additional, Castellano, D., additional, Bamias, A., additional, Chi, K.N., additional, van der Heijden, M.S., additional, Matsubara, N., additional, Hussain, S., additional, Flechon, A., additional, Alekseev, B.Y., additional, Yu, E.Y., additional, Walgren, R.A., additional, Russo, F., additional, Zimmermann, A.H., additional, Bell-Mcguinn, K.M., additional, and Powles, T.B., additional

Published
2018
Full Text
View/download PDF

103. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

Author

Matsubara, N., primary, Chi, K.N., additional, Ozguroglu, M., additional, Rodriguez Antolin, A., additional, Feyerabend, S., additional, Fein, L., additional, Alekseev, B.Y., additional, Sulur, G., additional, Protheroe, A., additional, Li, S., additional, Mundle, S.D., additional, De Porre, P., additional, Tran, N., additional, and Fazazi, K., additional

Published
2018
Full Text
View/download PDF

104. Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer

Author

Bamias, A., primary, Van Der Heijden, M., additional, De Wit, R., additional, Fléchon, A., additional, Nishiyama, H., additional, Castellano, D., additional, Drakaki, A., additional, Matsubara, N., additional, Liepa, A., additional, Zimmermann, A., additional, Bell-Mcguinn, K., additional, Hamid, O., additional, Petrylak, D., additional, Powles, T., additional, and Necchi, A., additional

Published
2018
Full Text
View/download PDF

105. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Petrylak, Dp, de Wit, R, Chi, Kn, Drakaki, A, Sternberg, Cn, Nishiyama, H, Castellano, D, Hussain, S, Flechon, A, Bamias, A, Yu, Ey, van der Heijden, M, Matsubara, N, Alekseev, B, Necchi, A, Geczi, L, Ou, Yc, Coskun, H, Su, Wp, Hegemann, M, Percent, Ij, Lee, Jl, Tucci, M, Semenov, A, Laestadius, F, Peer, A, Tortora, Giampaolo, Safina, S, del Muro, Xg, Rodriguez-Vida, A, Cicin, I, Harputluoglu, H, Widau, Rc, Liepa, Am, Walgren, Ra, Hamid, O, Zimmermann, Ah, Bell-McGuinn, Km, Powles, T, Tortora, G (ORCID:0000-0002-1378-4962), Petrylak, Dp, de Wit, R, Chi, Kn, Drakaki, A, Sternberg, Cn, Nishiyama, H, Castellano, D, Hussain, S, Flechon, A, Bamias, A, Yu, Ey, van der Heijden, M, Matsubara, N, Alekseev, B, Necchi, A, Geczi, L, Ou, Yc, Coskun, H, Su, Wp, Hegemann, M, Percent, Ij, Lee, Jl, Tucci, M, Semenov, A, Laestadius, F, Peer, A, Tortora, Giampaolo, Safina, S, del Muro, Xg, Rodriguez-Vida, A, Cicin, I, Harputluoglu, H, Widau, Rc, Liepa, Am, Walgren, Ra, Hamid, O, Zimmermann, Ah, Bell-McGuinn, Km, Powles, T, and Tortora, G (ORCID:0000-0002-1378-4962)

Abstract

Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population.Methods We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 sites in 23 countries. Previous treatment with one immune-checkpoint inhibitor was permitted. Patients were randomised (1:1) using an interactive web response system to receive intravenous docetaxel 75 mg/m(2) plus either intravenous ramucirumab 10 mg/kg or matching placebo on day 1 of repeating 21-day cycles, until disease progression or other discontinuation criteria were met. The primary endpoint was investigator-assessed progression-free survival, analysed by intention-to-treat in the first 437 randomised patients. This study is registered with ClinicalTrials.gov, number NCT02426125.Findings Between July, 2015, and April, 2017, 530 patients were randomly allocated either ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267). Progression-free survival was prolonged significantly in patients allocated ramucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76 months [2.60-2.96]; hazard ratio [HR] 0.757, 95% CI 0.607-0.943; p=0.0118). A blinded independent central analysis was consistent with these results. An objective response was achieved by 53 (24.5%, 95% CI 18.8-30.3) of 216 patients allocated ramucirumab and 31 (14.0%, 9.4-18.6) of 221 assigned placebo. The most frequently reported treatment-emergent adverse events, regardless of causality, in either treatment group (any grade) were fatigue, alopecia, diarrhoea, decreased appetite, and nausea. These events occurred predominantly at g

Published
2017

106. Can Periprocedural Hypotension in Carotid Artery Stenting Be Predicted ? : A Carotid Morphologic Autonomic Pathologic Scoring Model Using Virtual Histology to Anticipate Hypotension

Author

TSURUMI, A., MIYACHI, S., HOSOSHIMA, O., IZUMI, T., OHSHIMA, T., MATSUBARA, N., KINKORI, T., NAITO, T., and WAKABAYASHI, T.

Subjects
carotid ultrasound, interventional neuroradiology, carotid stenosis, stenting, Virtual Histology, pathology, cardiovascular diseases
Abstract

Periprocedural hypotension, which frequently occurs during carotid artery stenting (CAS), is an important risk factor for complications such as stroke or death after CAS. To determine if a scoring model can be established to predict periprocedural hypotension (systolic blood pressure < or = 90 mm Hg) and prolonged periprocedural hypotension (requiring vasopressor for > 3 hours) in CAS, we conducted a prospective cohort study of patients undergoing interventional treatment of cervical carotid artery stenosis in an urban tertiary referral hospital from April 2006 to April 2007. Forty-eight stenotic lesions in 45 consecutive patients treated with CAS were included in the study. Multivariate analysis showed three independent risk factors of periprocedural hypotension; "fibrous plaque on Virtual Histology" (P = 0.029), "stenotic lesion involving both the common carotid artery and internal carotid artery on angiogram" (P = 0.004), and "patients without history of diabetes mellitus" (P = 0.020). Further, "distance between carotid bifurcation and point of minimum lumen size < or = 10 mm on angiogram" (P = 0.003) was an independent risk factor of prolonged periprocedural hypotension. Carotid morphologic autonomic pathologic score (carotid MAPS), determined by adding one point for each of those risk factors (total 0 to 4), had good discrimination for both periprocedural hypotension (area under receiver operating characteristic curve: ROC AUC = 0.876; SE 0.053) and prolonged periprocedural hypotension (ROC AUC = 0.811; SE 0.066). Carotid MAPS is useful for predicting periprocedural hypotension and prolonged periprocedural hypotension during CAS., 名古屋大学博士学位論文 学位の種類 : 博士(医学)(課程) 学位授与年月日:平成21年3月25日 靍見有史氏の博士論文として提出された

Published
2009

109. Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO)

Author

Chi, K., primary, Protheroe, A., additional, Rodriguez Antolin, A., additional, Facchini, G., additional, Suttmann, H., additional, Matsubara, N., additional, Ye, Z-Q., additional, Keam, B., additional, Li, T., additional, McQuarrie, K., additional, Jia, B., additional, De Porre, P., additional, Martin, J., additional, Todd, M.B., additional, and Fizazi, K., additional

Published
2017
Full Text
View/download PDF

110. RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

Author

Petrylak, D.P., primary, Chi, K.N., additional, Drakaki, A., additional, Sternberg, C.N., additional, de Wit, R., additional, Nishiyama, H., additional, Yu, E.Y., additional, Castellano, D., additional, Hussain, S., additional, Percent, I.J., additional, Fléchon, A., additional, Bamias, A., additional, van der Heijden, M.S., additional, Matsubara, N., additional, Alekseev, B., additional, Walgren, R.A., additional, Hamid, O., additional, Zimmermann, A.H., additional, Bell-Mcguinn, K.M., additional, and Powles, T., additional

Published
2017
Full Text
View/download PDF

111. Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC)

Author

Takahashi, S., primary, Fujiwara, Y., additional, Matsubara, N., additional, Tomomatsu, J., additional, Iwasa, S., additional, Yamasaki, A., additional, Endo, C., additional, Yokoyama, S., additional, and Doi, T., additional

Published
2017
Full Text
View/download PDF

113. First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors

Author

Kuboki, Y., primary, Matsubara, N., additional, Bando, H., additional, Shitara, K., additional, Yoh, K., additional, Kojima, T., additional, Ohno, I., additional, Takahashi, H., additional, Harano, K., additional, Kondo, S., additional, Hirai, H., additional, Morizane, C., additional, and Doi, T., additional

Published
2017
Full Text
View/download PDF

115. 929P - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study

Author

van der Heijden, M., Powles, T., Petrylak, D., de Wit, R., Chi, K., Necchi, A., Sternberg, C.N., Matsubara, N., Nishiyama, H., Castellano, D., Hussain, S., Bamias, A., Hozak, R., Rhodes, R., Xia, M.S., Rasmussen, E., Aggarwal, A., Wijayawardana, S., Bell-McGuinn, K.M., and Drakaki, A.

Published
2019
Full Text
View/download PDF

116. 847PD - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

Author

de Bono, J.S., Fizazi, K., Saad, F., Shore, N., Sandhu, S.K., Mehra, N., Kolinsky, M., Roubaud, G., Özgüroǧlu, M., Matsubara, N., Gedye, C., Choi, Y.D., Padua, C., Goessl, C., Kohlmann, A., Corcoran, C., Adelman, C.A., Allen, A., Burgents, J., and Hussain, M.

Published
2019
Full Text
View/download PDF

117. 208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations.

Author

Matsubara, N., Loriot, Y., Burgess, E.F., Park, S.H., Huddart, R.A., Ku, J.H., Tran, B., Triantos, S., Deprince, K., Mukhopadhyay, S., Hemaya, R., Zhuo, J., and Siefker-Radtke, A.O.

Subjects
*FIBROBLAST growth factor receptors, *TRANSITIONAL cell carcinoma, *METASTASIS, *SUBGROUP analysis (Experimental design), *CANCER chemotherapy
Published
2023
Full Text
View/download PDF

118. Microarray di nuova concezione specifico per CpG islands: applicabilità alla valutazione semiquantitativa dello stato di metilazione del promotore MGMT nel Glioblastoma

Author

PASINI, ALICE, PRACUCCI A., GIORDANO, EMANUELE DOMENICO, CAVALCANTI S., CERASOLI S., GUIDUCCI G., CREMONINI A. M., BIANCHI E., PAIOLI G., MATSUBARA N., IORIO P., PASINI A., PRACUCCI A., GIORDANO E., CAVALCANTI S., CERASOLI S., GUIDUCCI G., CREMONINI A.M., BIANCHI E., PAIOLI G., MATSUBARA N., and IORIO P.

Subjects
DNA, methylation, epigenetic, glioblastoma, MGMT
Abstract

Lo stato di metilazione del promotore del gene MGMT nel glioblastoma e’ ormai ben accettato come indicatore predittivo di buona risposta clinica al trattamento con alchilanti. Tale ruolo predittivo si fonda sulle evidenze fornite dai ben noti studi prospettici recentemente condotti sull’argomento. Tuttavia nella gestione dei pazienti in contesti operativi principalmente assistenziali e non dedicati alla ricerca la validazione di questo marcatore molecolare e’ una importante operazione traslazionale che deve essere ancora in gran parte compiuta. Per un impiego diagnostico i metodi di valutazione dello stato di metilazione di MGMT dovrebbero avere caratteristiche di standardizzazione, semplicita’ di esecuzione, precisione ed accuratezza elevate e costo contenuto. Da questo punto di vista la tecnologia analitica dei microarray specifici per CpG islands e’ disponibile come alternativa ai metodi classici (Methylation Specific PCR-MSP e sequenziamento) avendo come limite principale il costo elevato. Recentemente e’ stato sviluppato e validato per lo studio epigenetico di MGMT un nuovo tipo di CpG island microarray che potrebbe essere impiegato per uso diagnostico con costi estremamente contenuti. Inoltre tale tipo di tecnologia permette rispetto alla classica MSP la valutazione di un numero maggiore di CpG islands nella regione del promotore di MGMT fornendo una valutazione semiquantitativa dello stato di metilazione, la quale potrebbe aumentare la capacita’ discriminativa del test. Il microarray e’ stato validato per lo studio del carcinoma del colon. In questo studio viene descritta l’applicabilita’ di tale microarray alla valutazione di MGMT nel glioblastoma, tramite lo studio di 14 casi.

Published
2006

119. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation

Author

Tamura, K., primary, Shitara, K., additional, Naito, Y., additional, Shimomura, A., additional, Fujiwara, Y., additional, Yonemori, K., additional, Shimizu, C., additional, Shimoi, T., additional, Kuboki, Y., additional, Matsubara, N., additional, Kitano, A., additional, Jikoh, T., additional, Fujisaki, Y., additional, Yver, A., additional, and Doi, T., additional

Published
2016
Full Text
View/download PDF

122. 797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

Author

Matsubara, N., Chi, K.N., Ozguroglu, M., Rodriguez Antolin, A., Feyerabend, S., Fein, L., Alekseev, B.Y., Sulur, G., Protheroe, A., Li, S., Mundle, S.D., De Porre, P., Tran, N., and Fazazi, K.

Published
2018
Full Text
View/download PDF

123. 865PD - RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Author

Petrylak, D.P., Sternberg, C.N., Drakaki, A., de Wit, R., Nishiyama, H., Necchi, A., Castellano, D., Bamias, A., Chi, K.N., van der Heijden, M.S., Matsubara, N., Hussain, S., Flechon, A., Alekseev, B.Y., Yu, E.Y., Walgren, R.A., Russo, F., Zimmermann, A.H., Bell-Mcguinn, K.M., and Powles, T.B.

Published
2018
Full Text
View/download PDF

125. Abstracts of the Nineteenth Annual Meeting of the Japanese Society of Biometeorology, Hamamatsu, 28–29 November 1980

Author

Okuwaki, Y., Iwami, K., Kikuchi, M., Fujita, K., Sawada, S., Yamamoto, S., Sudo, A., Murakami, N., Mohri, M., Nagasaka, T., Shibata, H., Hirata, K., Yurugi, R., Kondo, Y., Moriya, K., Hiroshige, T., Kurahashi, M., Kuroshima, A., Yahata, T., Doi, K., Harimura, Y., Tochihara, Y., Ohnaka, T., Matsui, J., Tanaka, M., Yoshida, K., Mayuzumi, M., Tanaka, N., Tsujita, J., Hori, S., Morimoto, T., Miki, K., Nose, H., Yamada, S., Ohara, K., Okuda, N., Sato, H., Isobe, Y., Hasegawa, Y., Miyagawa, T., Ogawa, T., Asayama, M., Sugenoya, J., Matsui, R., Igawa, S., Kashimura, O., Nakai, S., Kita, H., Ueda, G., Takeoka, M., Koshihara, Y., Tsuchiya, K., Ohwatari, N., Kosaka, M., Nagai, M., Iriki, M., Pleschka, K., Kiyohara, T., Hori, T., Nakashima, T., Shibata, M., Osaka, T., Sugano, T., Araki, T., Namihira, G., Nagata, H., Ishigure, K., Shimaoka, K., Mori, S., Hara, M., Shinohara, T., Nagao, Y., Okabe, N., Hamaguchi, K., Sasaki, T., Komori, A., Saito, S., Sakai, A., Yoshimura, K., Fukushima, M., Kubo, K., Kobayashi, T., Shimizu, N., Minamino, O., Naruse, T., Isoda, N., Kamiyama, K., Midorikawa, T. T., Niwa, K., Nakayama, T., Agishi, Y., Yamaoka, S., Yamasaki, M., Momiyama, M., Tajima, Y., Katayama, K., Nakamura, Y., Matsubara, N., Kimura, T., Shimura, M., and Miura, T.

Published
1982
Full Text
View/download PDF

126. Abstracts of the Twenty-second Annual Meeting of the Japanese Society of Biometeorology, Kanazawa, 28–29 October 1983

Author

Hirose, F., Tokura, H., Shibuya, I., Tamura, M., Doi, K., Isobe, Y., Hasegawa, Y., Ohara, K., Ueda, G., Sakai, A., Kobayashi, T., Kubo, K., Fukushima, M., Yoshimura, K., Shibamoto, T., Yasaki, K., Ohyabu, Y., Nishibayashi, Y., Honda, Y., Tsujita, J., Hori, S., Watanuki, M., Miyatani, S., Kajiwara, N., Sasaki, T., Hayashi, O., Aoki, N., Shimura, A., Kikuchi, M., Yamamoto, S., Sawada, S., Yasukouchi, A., Nose, N., Morimoto, T., Ogura, K., Takeoka, M., Koshihara, Y., Sudo, A., Kuroshima, A., Habara, Y., Uehara, A., Murazumi, K., Yahata, T., Ohno, T., Mohri, M., Tanaka, M., Matsui, J., Yamazaki, S., Tochihara, Y., Ohnaka, T., Yoshida, K., Nishi, Y., Mochida, T., Yokoyama, S., Ogino, H., Nonaka, K., Shimura, M., Miura, T., Hanawa, K., Yorimoto, A., Igawa, S., Kita, H., Horie, G., Sakurai, Y., Noguchi, T., Matsubara, N., Okamoto, S., Satoh, S., Yamashita, Y., Kawamura, M., Nakajima, T., Sugai, K., Tsuzuki, S., Imai-Matsumura, K., Nakayama, T., Ishikawa, Y., Tanaka, H., Kanosue, K., Ohnuki, Y., Matsumura, K., Ohnuki, Y., Shibata, M., Hori, T., Kiyohara, T., Nakashima, T., Murakami, N., Simon-Oppermann, Ch., Gray, D. A., Simon, E., Furuyama, F., Ogawa, T., Miyagawa, T., Asayama, M., Terai, Y., Sugenoya, J., Ohnishi, N., Fujimatsu, H., Niwa, K., Kosaka, M., Ohwatari, N., Fujiwara, M., and Tsuchiya, K.

Published
1985
Full Text
View/download PDF

127. Abstracts of the Twenty-First Annual Meeting of the Japanese Society of Biometeorology, Sapporo, 4–5 October

Author

Hayashi, O., Aoki, N., Shimura, A., Kikuchi, M., Tsuzuki, S., Kubo, K., Sasaki, T., Asayama, M., Fujimatsu, H., Miyagawa, T., Terai, Y., Sugenoya, J., Ogawa, T., Ohnishi, N., Takano, T., Miyazaki, Y., Motohashi, Y., Yasukouchi, A., Iwanaga, K., Koya, Y., Tochihara, Y., Ohnaka, T., Yamazaki, S., Tanaka, M., Yoshida, K., Kashimura, Osamu, Murakami, N., Konda, N., Shiraki, K., Sagawa, S., Igawa, S., Morikawa, T., Kashimura, O., Kita, H., Yamamoto, S., Sudo, A., Sawada, S., Kobayashi, Y., Kawagoe, K., Horie, G., Sakurai, Y., Matsubara, N., Miki, K., Morimoto, T., Nose, H., Ito, T., Yamada, S., Sakai, A., Ueda, G., Yasaki, K., Shibamoto, T., Yoshimura, K., Fukushima, M., Kobayashi, T., Ohwatari, N., Fujiwara, M., Tsuchiya, K., Kosaka, M., Sakaguchi, E., Osada, H., Sakaguchi, T., Yurugi, R., Yanagidaira, Y., Takeoka, M., Koshihara, Y., Tsujita, J., Tohori, M., Tanaka, N., Hori, S., Araki, T., Fujimatu, H., Sugano, Y., Nagasaka, T., Nunomura, T., Ohmae, O., Shibata, H., Tsurutani-Midorikawa, T., Niwa, K., Nakayama, T. T., Horikoshi, T., Mochida, T., Yokoyama, S., Ogino, H., Hori, T., Kiyohara, T., Shibara, M., Nakashima, T., Ohnuki, Y., Ishikawa, Y., Nakayama, T., Isobe, Y., Kimura, T., Shimura, M., Miura, T., Momiyama, M., Nakamura, Y., Yamasaki, M., Yamaoka, S., Ishigure, K., Nagata, H., Doi, K., Kuroshima, A., Inomoto, T., Yazaki, K., and Mohri, M.

Published
1984
Full Text
View/download PDF

134. LBA4_PR - RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

Author

Petrylak, D.P., Chi, K.N., Drakaki, A., Sternberg, C.N., de Wit, R., Nishiyama, H., Yu, E.Y., Castellano, D., Hussain, S., Percent, I.J., Fléchon, A., Bamias, A., van der Heijden, M.S., Matsubara, N., Alekseev, B., Walgren, R.A., Hamid, O., Zimmermann, A.H., Bell-Mcguinn, K.M., and Powles, T.

Published
2017
Full Text
View/download PDF

145. High frequency of low-level microsatellite instability in early colorectal cancer

Author

Kambara T, Matsubara N, Nakagawa H, Notohara K, Takeshi Nagasaka, Yoshino T, Isozaki H, Gb, Sharp, Shimizu K, Jass J, and Tanaka N

Subjects
Chromosome Aberrations, Male, Genes, ras, Humans, Loss of Heterozygosity, Female, Middle Aged, Colorectal Neoplasms, Aged, Microsatellite Repeats
Abstract

Molecular events in early colorectal cancers (CRCs) have not been well elucidated because of the low incidence of early CRCs in clinical practice. Therefore, we studied 104 sporadic early CRCs with invasion limited to submucosa compared with 116 advanced CRCs. Loss of heterozygosity as well as microsatellite instability (MSI) status was examined. A significantly high frequency of low-level MSI (MSI-L) phenotype was detected in early CRCs (51.0%) compared with advanced CRCs (25.9%; P = 0.0001). In early and advanced CRCs, samples with MSI-L phenotype differed from microsatellite stable (MSS) phenotype with respect to loss of heterozygosity at 1p32 and 8p12-22. MSI-L is a frequent genetic event in early CRCs and may be a novel pathway in colorectal carcinogenesis distinct from both MSI-H and MSS.

Published
2001

150. AB0162 Shared decision making between patient and rheumatologist using a novel touch-panel system for treating rheumatoid arthritis to target

Author

Kunii, A., primary, Yokogawa, N., additional, Oguma, T., additional, Nakahara, K., additional, Matsubara, N., additional, Morimoto, M., additional, Yokoyama, K., additional, Warashina, A., additional, Todoroki, E., additional, Shimada, K., additional, Kagawa, K., additional, Ohshima, S., additional, and Sugii, S., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results